OBJECTIVES:
To evaluate differences in bone turnover markers in patients with T2DM according to the presence of osteoporosis diagnosed by different classifications and FRAX index.
METHODS:
Cross-sectional study including 78 T2DM patients.
BMD was evaluated by DXA (Hologic QDR 4500).
Patients were classified as having or not osteoporosis according to WHO criteria, new criteria from Schwartz et al. and FRAX index.
We determined: bone-specific alkaline phosphatase (BSAP) (OCTEIA TM IDS Ltd Boldon UK), osteocalcin (OC) (DiaSorin, Stillwater, Minnesota USA); TRA5b (Bone TRAP ® Assay. IDS Ltd); and CTX (Elecsys ß CrossLaps,Roche Diagnostics SL, Barcelona, Spain).
Results were analysed by SPSS 15.0. 
RESULTS:

T2DM
BONE TURNOVER MARKERS ACCORDING TO THE THREE CLASSIFICATIONS
CONCLUSIONS:
Our results suggest that higher CTX concentrations may indicate which T2DM patients are suitable for osteoporosis treatment, although the measurement of CTX does not constitute a fracture risk factor independently of BMD. However, it may help in the identification of patients in whom DXA must be done. 
